H.C. Wainwright assumed coverage of MannKind (MNKD) with a Buy rating and $9 price target The firm views the company’s pipeline as largely overlooked at current share levels. MannKind’s valuation does not balance the potential headwinds with potential tailwinds on the Tyvaso royalty, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind’s Afrezza: A Promising Undervalued Opportunity in Diabetes Treatment
- MannKind’s Growth Potential and Strategic Positioning Amidst Near-Term Uncertainties: A Buy Rating by Faisal Khurshid
- MannKind’s Afrezza: A Significantly Undervalued Investment Opportunity with Promising Clinical Data
- MannKind’s Strategic Growth Potential and Market Positioning: A Buy Recommendation
- MannKind Stockholders Approve Board and Compensation